MIT researchers develop injectable mini-livers

Researchers at the Massachusetts Institute of Technology (MIT) are developing injectable ‘mini-livers’ as a less invasive alternative to traditional organ transplants. Led by Professor Sangeeta Bhatia, the team is working to restore hepatocyte activity to address the chronic shortage of organ donors and reduce the risks associated with major surgical interventions.

The technology utilizes specialized cells paired with hydrogel microspheres. These spheres remain compact enough to behave like a liquid, allowing them to be administered via a syringe. Once inside the body, the material regains its solid structure to function as healthy tissue. These units are designed to perform essential metabolic and detoxification tasks, potentially serving as a temporary ‘bridge’ for patients with acute liver failure or managing chronic diseases.

While results in mouse models have been encouraging, several technical and regulatory hurdles remain. Key challenges include ensuring sufficient vascularization, preventing immune rejection, guaranteeing long-term integration, and achieving large-scale production that meets sanitary standards. Rigorous preclinical and clinical trials are required before human application.